Funding Opportunity PAR-19-218 from the NIH Guide for Grants and Contracts. The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to applications from training programs at research-active institutions (i.e., those with a 3-year average of NIH Research Project Grant funding less than $7.5 million total costs).

Notice NOT-CA-19-034 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-20-004 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute invites applications for a Research Coordinating Center (RCC) to support projects from RFA-HL-20-003 Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR), which will test late-stage (T4) implementation research strategies for optimally and sustainably delivering proven-effective, evidence-based multi-level interventions to reduce or eliminate cardiovascular and/or pulmonary health disparities, and that promote and improve population health in high-burden communities (see RFA-HL-20-003). The DECIPHeR RCC will coordinate activities across all of the DECIPHeR projects, including coordinating and managing in-person and virtual network steering committee meetings and working groups; promoting collaboration and communication among investigators and the broader research community; coordinating network outreach activities; promoting skills development in implementation science; and organizing, implementing, and managing a global implementation data safety and monitoring board (DSMB) and providing clinical study and site monitoring for DECIPHeR awards. For the purpose of this FOA, late-stage (T4) implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions into routine clinical and public health practice and community-based settings and maximize the positive impact on population health.

Funding Opportunity RFA-HL-20-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications for projects that propose to test T4 implementation research strategies for delivering proven-effective, evidence-based community-level interventions for reducing or eliminating cardiovascular and/or pulmonary health disparities, and that promote and improve population health in high-burden communities. For the purpose of this FOA, T4 implementation research is defined as research to identify strategies to enhance sustainable uptake of proven-effective interventions in routine clinical and public health practice and community-based settings to achieve maximal population health impact.

Notice NOT-AI-19-051 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-046 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-20-010 from the NIH Guide for Grants and Contracts. This funding opportunity announcement is intended to support a Data Coordinating Center (DCC) to conduct the activities of the BLOODSAFE program. to enhance the availability and delivery of safe blood for transfusion for patients in low or lower-middle income countries in Sub-Saharan Africa. The primary responsibilities of the DCC are to coordinate the activities of the research consortium, assist with program oversight by NHLBI, provide expertise in study design and management as well as data management and analysis, develop common measures and outcomes, ensure data quality, and facilitate collaboration and mutual learning among all research teams.

Funding Opportunity RFA-HL-20-009 from the NIH Guide for Grants and Contracts. This funding opportunity announcement will supportprojectsto enhance the availability and delivery of safe blood to be used for transfusion in patients from low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (SSA). For example, ensuring that children with malaria or sickle cell disease and pregnant women who suffer from obstetric hemorrhage have access to safe transfusion therapies is of high programmatic interest. BLOODSAFE will support projects that develop and test feasible, effective and sustainable strategies to increase the number of safe blood donors, to improve quality and safety of blood supplies, and to enhance blood delivery to patients in need, especially in remote settings.

Notice NOT-ES-19-006 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-047 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DE-19-010 from the NIH Guide for Grants and Contracts. The Purpose of this Funding Opportunity Announcement (FOA) is to provide support for the operation of a multidisciplinary Dental, Oral and Craniofacial Tissue Regeneration Consortium (DOCTRC) that will facilitate advancing promising strategies for regeneration and reconstruction of dental, oral and craniofacial (DOC) tissues to clinical trials. DOCTRC will be composed of the Resource Centers (RCs) and associated Interdisciplinary Translational Projects (ITPs) that were built during Stage 2 of the DOCTRC effort. In Stage 3, the RCs will capitalize on its clinical, scientific, industrial and regulatory expertise, to deliver technical support, research capacity, administrative infrastructure and regulatory expertise to the ITPs and guide them through pre-clinical studies toward initiation of clinical trials.

Funding Opportunity RFA-DK-19-006 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.

Funding Opportunity PAR-19-215 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIBIB R25 program is to support educational activities that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nations needs in biomedical research and healthcare technologies. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA encourages applications from institutions that propose to establish new or to enhance existing team-based design courses or programs in undergraduate biomedical engineering departments or other degree-granting programs with biomedical engineering tracks/minors. This FOA targets undergraduate students. While current best practices such as multidisciplinary/interdisciplinary education, introduction to the regulatory pathway and other issues related to the commercialization of medical devices, and clinical immersion remain encouraged components of a strong BME program, this FOA also challenges institutions to propose other novel, innovative and/or ground-breaking activities that can form the basis of the next generation of biomedical engineering design education.

Notice NOT-HD-19-008 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-007 from the NIH Guide for Grants and Contracts

Notice NOT-RM-19-003 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-214 from the NIH Guide for Grants and Contracts. The overall goal of this initiative is to identify neurophysiological measures potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

Funding Opportunity RFA-DK-19-501 from the NIH Guide for Grants and Contracts. The Chronic Kidney Disease Biomarkers Consortium [CKD BioCon] was established in September 2009 as a result of RFA-DK-08-015 [Chronic Kidney Disease Biomarker Discovery and Validation Consortium (U01)] to develop, validate and qualify biomarkers based on existing biosamples from well-characterized CKD patients with longitudinal follow-up. The second phase of the CKD BioCon was funded in September 2014, pursuant to RFA DK-14-011. Two additional Centers were brought into the Consortium in 2015. The CKD BioCon currently consists of eight Participating Clinical Centers (PCCs) and is actively engaged in multiple research protocols. The DCC's goalover the next two years will enhance biomarker research in CKD by a) providing ongoing logistical support, expertise and statistical support to consortial work involving one or more PCCs, b) supervising the proposal, approval and progress of consortial studies, and supporting the conduct of the studies, and c) supervising transfer of data and samples between members of the consortium and repository activities of the consortium, as well as the NIDDK repository.

Funding Opportunity PAR-19-212 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain. Research of interest includes but is not limited to Stage II and Stage III efficacy research.

Funding Opportunity PAR-19-213 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain. Research of interest includes but is not limited to Stage I research.